Erythropoiesis-Stimulating Agents (ESAs)
ESAs, such as erythropoietin-stimulating agents, are synthetic forms of erythropoietin. They are often prescribed to stimulate the production of red blood cells and manage anemia in CKD.
Our nephrologists will adjust the doses based on hemoglobin levels. Regular monitoring is essential to avoid excessive increases in hemoglobin, which can lead to cardiovascular complications.
Monitoring and Adjustments
Regular monitoring of hemoglobin, ferritin, and transferrin saturation levels is essential to assess the effectiveness of the treatment plan. Our nephrologist may need to adjust treatment based on the individual’s response, and the underlying causes of anemia should be addressed.
In severe cases of anemia or if other treatments are ineffective, blood transfusions may be considered. However, this is generally reserved for situations where other interventions have failed or when there is an urgent need to raise hemoglobin levels.
It’s important for individuals with CKD and anemia to work closely with our team at the nephrology department to develop a comprehensive treatment plan. Regular monitoring and open communication with our team is crucial for adjusting interventions and ensuring optimal management of anemia in chronic kidney disease.